Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience

Abstract

BackgroundIbrutinib is a Bruton’s tyrosine kinase inhibitor, which is United States Food and Drug Administration (FDA)-approved for chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström’s macroglobulinemia. Ibrutinib is associated with atrial fibrillation and bleeding events. Our aim is to determine the management of prior atrial fibrillation when starting ibrutinib, as well as ibrutinib-induced atrial fibrillation. Our focus is on which rate and rhythm control strategies to use and decisions regarding the use of antiplatelet and anticoagulation agents.Materials and MethodsWe conducted a retrospective descriptive study of case records over a three-year period from February 2014 to February 2017. We reviewed 597 patient charts from the Cleveland Clinic database. Ibrutinib was started in 43 patients. Of those, 10 had atrial fibrillation prior to starting ibrutinib and four developed atrial fibrillation while on ibrutinib. Data was collected for demographic details, co-morbid conditions, CHA2DS2-VASc (congestive heart failure, hypertension, age, diabetes mellitus, prior stroke, transient ischemic attack or thromboembolism, vascular disease, age, and sex category) score, HAS-BLED (hypertension, abnormal renal and liver function, stroke, bleeding, labile INR, elderly, and drugs or alcohol) score, and drugs used for antiplatelet effects, for anticoagulation, and for rate and rhythm control. Outcomes for embolic and bleeding events were assessed.ResultsOf the 43 patients, 14 (32.5%) had or developed atrial fibrillation; 10 (23.26%) had prior atrial fibrillation, and four (9.30%) developed atrial fibrillation after starting ibrutinib. The majority were males (71.42%) and Caucasian (71.42%). The disease breakdown was chronic lymphocytic leukemia (42.86%), mantle cell lymphoma (50%), and Waldenström’s macroglobulinemia (7.14%). The mean starting dose of ibrutinib in patients with prior atrial fibrillation was 569 mg and for patients who developed atrial fibrillation was 420 mg. In the 10 patients who had atrial fibrillation prior to ibrutinib, all 10 were on beta blockers, one was on diltiazem, three were on amiodarone, one was on flecainide, one was on digoxin, and one was on Tikosyn® (Pfizer, Inc., New York, NY). The ibrutinib dose was decreased/discontinued in two patients. In patients who developed atrial fibrillation after starting ibrutinib, three were on beta blockers, two on amiodarone, and one on Tikosyn. Ibrutinib was discontinued in one patient. In patients who had prior atrial fibrillation, three were on warfarin, one on enoxaparin, and two on apixaban. In three patients, aspirin and enoxaparin were discontinued. In patients who developed atrial fibrillation after starting ibrutinib, enoxaparin was given to two and apixaban to one. None of the patients had a stroke, transient ischemic attack (TIA), or bleeding events.ConclusionsFrom our study, we concluded that ibrutinib can be safely given in the presence of atrial fibrillation, and when atrial fibrillation was induced, we further concluded that...

Pre-Existing Cardiovascular Disease Increases Risk of Atrial Arrhythmia in Cancer Patients Treated With Ibrutinib

“…This also presents a clinical conundrum in the decision of whether to discontinue ibrutinib at the expense of progressive oncologic disease or to continue ibrutinib treatment with the risk of cardiovascular compromise. Our study did not reveal a difference in the rate of ibrutinib discontinuation in our two cohorts; however, atrial brillation remains the most common cause of ibrutinib discontinuation in treated patients (34,35).…”

Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib

“…Management of IRAF poses unique challenges given the increased risk of bleeding associated with ibrutinib and various medication interactions 21,22 . It is estimated that ibrutinib is associated with bleeding in 3%–5% of patients, likely mediated by platelet dysfunction, 23 and potentially compounded by underlying thrombocytopenia in the setting of hematologic malignancy 24 .…”

“…17 It was proposed that in diseased ventricular states, PACS has increased importance as it helps maintain cardiac output and control pulmonary capillary wedge pressure. 17 The 21,22 It is estimated that ibrutinib is associated with bleeding in 3%-5% of patients, likely mediated by platelet dysfunction, 23 and potentially compounded by underlying thrombocytopenia in the setting of hematologic malignancy. 24 The majority of ibrutinib-related bleeding events tend to be mild and do not require medication interruption or dose modification.…”

Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations

“…Notwithstanding, if AF can be controlled with the adequate management and the use of specific anti-arrhythmic therapy, ibrutinib may be reintroduced. Beta-blockers are the preferred choice for managing acute episodes of AF [69][70][71][72]. If this strategy is successful in resolving grade ≥3 AF, treatment with ibrutinib can be resumed unless anticoagulation therapy is required and poses an unacceptable risk of bleeding.…”